Published in Thromb Haemost on March 01, 2004
Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol (2007) 1.54
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol (2011) 1.37
A novel nonconsensus xenobiotic response element capable of mediating aryl hydrocarbon receptor-dependent gene expression. Mol Pharmacol (2011) 1.11
Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene (2008) 1.00
Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades. Biochem Res Int (2012) 0.96
A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem (2005) 0.94
Molecular imaging of vessels in mouse models of disease. Eur J Radiol (2009) 0.92
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays (2007) 0.92
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators Inflamm (2015) 0.90
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci (2008) 0.87
Functional stability of plasminogen activator inhibitor-1. ScientificWorldJournal (2014) 0.87
Protease nexin-1 expression is altered in human breast cancer. Cancer Cell Int (2006) 0.87
Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol (2010) 0.86
High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients. Breast Cancer Res (2012) 0.86
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion. Int J Exp Pathol (2005) 0.85
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol (2005) 0.82
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease. Mol Med Ther (2012) 0.80
Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers. Nucleic Acid Ther (2014) 0.79
Protein kinase A modulates transforming growth factor-β signaling through a direct interaction with Smad4 protein. J Biol Chem (2013) 0.79
Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library. Biochem J (2006) 0.79
Ah Receptor Pathway Intricacies; Signaling Through Diverse Protein Partners and DNA-Motifs. Toxicol Res (Camb) (2015) 0.77
Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis. PLoS One (2016) 0.76
Early gestation chorionic villi-derived stromal cells for fetal tissue engineering. World J Stem Cells (2015) 0.76
DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines. Chin J Cancer Res (2011) 0.75
Protein Microarrays for Quantitative Detection of PAI-1 in Serum. Chin J Cancer Res (2012) 0.75
Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat Neurosci (2010) 1.29
Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging (2010) 1.27
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36. Mol Imaging Biol (2013) 1.25
Biochemical properties of plasminogen activator inhibitor-1. Front Biosci (Landmark Ed) (2009) 1.22
Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol (2009) 1.15
Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins. Proc Natl Acad Sci U S A (2013) 1.13
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood (2003) 1.10
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem (2006) 1.04
Cantilever sensor for nanomechanical detection of specific protein conformations. Nano Lett (2005) 1.02
Cytoplasmic Prep1 interacts with 4EHP inhibiting Hoxb4 translation. PLoS One (2009) 0.99
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem Neurosci (2012) 0.96
The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett (2002) 0.96
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem (2011) 0.96
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia (2011) 0.93
Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J (2003) 0.91
A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem (2008) 0.91
Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase. Exp Cell Res (2013) 0.91
The effects of transmembrane sequence and dimerization on cleavage of the p75 neurotrophin receptor by γ-secretase. J Biol Chem (2012) 0.91
Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim Biophys Acta (2004) 0.91
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol (2004) 0.90
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. BMC Cancer (2011) 0.90
RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry (2010) 0.90
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Neuroimage (2013) 0.88
In vivo validation of free-space fluorescence tomography using nuclear imaging. Opt Lett (2010) 0.88
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J Struct Biol (2007) 0.88
A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem (2005) 0.87
Vitronectin in human breast carcinomas. Biochim Biophys Acta (2003) 0.87
Ultrasound research scanner for real-time synthetic aperture data acquisition. IEEE Trans Ultrason Ferroelectr Freq Control (2005) 0.87
Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal. FEBS Lett (2004) 0.87
Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist. Chem Biol (2013) 0.87
Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem (2003) 0.87
Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem (2004) 0.87
Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. J Biol Chem (2007) 0.86
Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin. Biochemistry (2012) 0.86
Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry. ACS Chem Biol (2013) 0.86
The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J (2003) 0.86
Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost (2003) 0.86
PAI-1 modulates cell migration in a LRP1-dependent manner via β-catenin and ERK1/2. Thromb Haemost (2015) 0.86
Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice. Psychopharmacology (Berl) (2014) 0.86
Local transient unfolding of native state PAI-1 associated with serpin metastability. Angew Chem Int Ed Engl (2014) 0.86
Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands. Biochem J (2003) 0.85
Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer (2010) 0.85
Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol (2007) 0.85
CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost (2005) 0.85
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem (2011) 0.84
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol (2008) 0.84
Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med (2010) 0.84